Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyHealthPartners Medicare Part D Step Therapy Covera…
    Ask Trek AI about this page
    CurrentHealthPartnersPolicy N/A

    2026 Medicare Part D Step Therapy Requirements

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists step therapy requirements for specific Part D drugs (notably Rytary/carbidopa-levodopa ER formulations and topical tazarotene) and the prior-use criteria required for coverage. It affects Medicare Part D beneficiaries and pharmacy/drug benefit administrators implementing step edits.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionRequire documentation of prior use of the specified lower-step therapy within the previous 12 months before approving Step 2 products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2distinct product groups with step therapy rules listed
    12 morequired prior-use lookback period
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    listed ER carbidopa-levodopa strengths

    Step Therapy Coverage Criteria

    Carbidopa-levodopa ER step criteria

    Rytary / carbidopa-levodopa ER products (Step 2)

    Prior use of carbidopa-levodopa immediate-release or extended-release tablets within the previous 12 months

    Medication history or prescription records must document use within the prior 12 months.

    Tazarotene step criteria

    Tazarotene topical products (Step 2)

    Prior use of tazarotene 0.1% cream within the previous 12 months

    Medication or prescription history must document prior use within 12 months; applies to listed 0.05% cream/gel Step 2 products.

    Product Index and Coding Details

    Index of listed product strengthsNDC
    CARBIDOPA ER 23.75 MG-LEVODOPA 95 MG CAPSULE,EXTENDED RELEASE
    CARBIDOPA ER 36.25 MG-LEVODOPA 145 MG CAPSULE,EXTENDED RELEASE
    CARBIDOPA ER 48.75 MG-LEVODOPA 195 MG CAPSULE,EXTENDED RELEASE
    CARBIDOPA ER 61.25 MG-LEVODOPA 245 MG CAPSULE,EXTENDED RELEASE
    tazarotene 0.05 % topical cream
    tazarotene 0.05 % topical gel
    tazarotene 0.1 % topical gel
    Prior use lookback — required prior-use lookback period
    Required lookback period12 months
    Applies toPrior therapy checks for listed Step 2 products (e.g., Rytary/carbidopa-levodopa ER and tazarotene Step 2 products)
    Evidence requiredMedication history or prescription records documenting use within the prior 12 months

    What Providers and Pharmacy Teams Must Do

    Step Therapy

    Step Therapy — Rytary (carbidopa‑levodopa ER)

    Step Therapy — Rytary (carbidopa‑levodopa ER): Step 2 Rytary products require documentation of prior use of carbidopa‑levodopa immediate‑release or extended‑release tablets within the previous 12 months. If prior use is not documented, coverage may be denied or prior authorization may be required.

    • Products affected Step 2: CARBIDOPA ER 23.75 MG‑LEVODOPA 95 MG CAPSULE, EXTENDED RELEASE
    • Products affected Step 2: CARBIDOPA ER 36.25 MG‑LEVODOPA 145 MG CAPSULE, EXTENDED RELEASE
    Step Therapy

    Step Therapy — Tazarotene topical

    Step Therapy — Tazarotene topical: Step 2 tazarotene products require documentation of prior use of tazarotene 0.1% cream within the previous 12 months.

    • tazarotene 0.1% topical gel

    Key Definitions

    Prior use requirement — definition
    DefinitionPrior use of the specified alternative medication within the previous 12 months is required before coverage of the Step 2 product.
    Example — Rytary (carbidopa-levodopa ER)Requires prior use of carbidopa-levodopa immediate-release or extended-release tablets within the previous 12 months.
    Example — Tazarotene topicalStep 2 tazarotene products require prior use of tazarotene 0.1% cream within the previous 12 months.
    EvidenceMedication or prescription history showing prior use within 12 months to support coverage determination.
    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionRequire documentation of prior use of the specified lower-step therapy within the previous 12 months before approving Step 2 products.
    SourceLink
    On This Page
    Step Therapy Coverage CriteriaProduct Index and Coding DetailsWhat Providers and Pharmacy Teams Must DoKey Definitions